|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SATB2 |
Gene summary for SATB2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SATB2 | Gene ID | 23314 |
| Gene name | SATB homeobox 2 | |
| Gene Alias | GLSS | |
| Cytomap | 2q33.1 | |
| Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | A0A024R3U6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 23314 | SATB2 | HTA11_3410_2000001011 | Human | Colorectum | AD | 6.87e-12 | -5.45e-01 | 0.0155 |
| 23314 | SATB2 | HTA11_78_2000001011 | Human | Colorectum | AD | 2.74e-02 | 1.40e-01 | -0.1088 |
| 23314 | SATB2 | HTA11_347_2000001011 | Human | Colorectum | AD | 5.42e-34 | 1.35e+00 | -0.1954 |
| 23314 | SATB2 | HTA11_83_2000001011 | Human | Colorectum | SER | 1.13e-03 | 3.78e-01 | -0.1526 |
| 23314 | SATB2 | HTA11_696_2000001011 | Human | Colorectum | AD | 4.18e-08 | 4.12e-01 | -0.1464 |
| 23314 | SATB2 | HTA11_866_2000001011 | Human | Colorectum | AD | 3.10e-09 | 5.14e-01 | -0.1001 |
| 23314 | SATB2 | HTA11_2992_2000001011 | Human | Colorectum | SER | 3.83e-08 | 3.06e-01 | -0.1706 |
| 23314 | SATB2 | HTA11_546_2000001011 | Human | Colorectum | AD | 7.91e-03 | 3.53e-01 | -0.0842 |
| 23314 | SATB2 | HTA11_7862_2000001011 | Human | Colorectum | AD | 1.38e-10 | 6.42e-01 | -0.0179 |
| 23314 | SATB2 | HTA11_8622_2000001021 | Human | Colorectum | SER | 1.77e-03 | -5.31e-01 | 0.0528 |
| 23314 | SATB2 | HTA11_7663_2000001011 | Human | Colorectum | SER | 6.88e-14 | 6.19e-01 | 0.0131 |
| 23314 | SATB2 | HTA11_10623_2000001011 | Human | Colorectum | AD | 1.37e-06 | 6.40e-01 | -0.0177 |
| 23314 | SATB2 | HTA11_6801_2000001011 | Human | Colorectum | SER | 3.60e-06 | 1.41e-01 | 0.0171 |
| 23314 | SATB2 | HTA11_7696_3000711011 | Human | Colorectum | AD | 3.59e-03 | -1.03e-01 | 0.0674 |
| 23314 | SATB2 | HTA11_7469_2000001011 | Human | Colorectum | AD | 1.81e-06 | 2.80e-01 | -0.0124 |
| 23314 | SATB2 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 3.31e-04 | 3.85e-01 | 0.294 |
| 23314 | SATB2 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 2.24e-06 | 2.48e-01 | 0.3859 |
| 23314 | SATB2 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 1.39e-101 | -1.36e+00 | 0.3005 |
| 23314 | SATB2 | F007 | Human | Colorectum | FAP | 1.07e-14 | -6.86e-01 | 0.1176 |
| 23314 | SATB2 | A002-C-010 | Human | Colorectum | FAP | 1.21e-07 | -3.02e-01 | 0.242 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0006325 | Colorectum | AD | chromatin organization | 119/3918 | 409/18723 | 4.85e-05 | 8.33e-04 | 119 |
| GO:0001649 | Colorectum | AD | osteoblast differentiation | 70/3918 | 229/18723 | 3.59e-04 | 4.18e-03 | 70 |
| GO:0048568 | Colorectum | AD | embryonic organ development | 112/3918 | 427/18723 | 4.60e-03 | 3.14e-02 | 112 |
| GO:0006338 | Colorectum | AD | chromatin remodeling | 70/3918 | 255/18723 | 7.44e-03 | 4.53e-02 | 70 |
| GO:0001503 | Colorectum | AD | ossification | 106/3918 | 408/18723 | 7.68e-03 | 4.64e-02 | 106 |
| GO:00016491 | Colorectum | SER | osteoblast differentiation | 56/2897 | 229/18723 | 2.49e-04 | 4.21e-03 | 56 |
| GO:00063251 | Colorectum | SER | chromatin organization | 89/2897 | 409/18723 | 4.15e-04 | 6.17e-03 | 89 |
| GO:00015031 | Colorectum | SER | ossification | 82/2897 | 408/18723 | 6.76e-03 | 4.78e-02 | 82 |
| GO:00063252 | Colorectum | MSS | chromatin organization | 107/3467 | 409/18723 | 7.22e-05 | 1.21e-03 | 107 |
| GO:00016492 | Colorectum | MSS | osteoblast differentiation | 64/3467 | 229/18723 | 2.91e-04 | 3.83e-03 | 64 |
| GO:00485681 | Colorectum | MSS | embryonic organ development | 100/3467 | 427/18723 | 6.00e-03 | 4.03e-02 | 100 |
| GO:00015032 | Colorectum | MSS | ossification | 96/3467 | 408/18723 | 6.09e-03 | 4.07e-02 | 96 |
| GO:00063253 | Colorectum | FAP | chromatin organization | 84/2622 | 409/18723 | 1.62e-04 | 2.47e-03 | 84 |
| GO:00016493 | Colorectum | FAP | osteoblast differentiation | 51/2622 | 229/18723 | 4.40e-04 | 5.22e-03 | 51 |
| GO:00015033 | Colorectum | FAP | ossification | 79/2622 | 408/18723 | 1.53e-03 | 1.37e-02 | 79 |
| GO:00485682 | Colorectum | FAP | embryonic organ development | 79/2622 | 427/18723 | 5.32e-03 | 3.49e-02 | 79 |
| GO:0030900 | Colorectum | FAP | forebrain development | 70/2622 | 379/18723 | 8.64e-03 | 4.98e-02 | 70 |
| GO:00063254 | Colorectum | CRC | chromatin organization | 74/2078 | 409/18723 | 1.48e-05 | 4.61e-04 | 74 |
| GO:00309001 | Colorectum | CRC | forebrain development | 66/2078 | 379/18723 | 1.36e-04 | 2.57e-03 | 66 |
| GO:00016494 | Colorectum | CRC | osteoblast differentiation | 41/2078 | 229/18723 | 1.36e-03 | 1.50e-02 | 41 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SATB2 | SNV | Missense_Mutation | c.2072N>T | p.Asp691Val | p.D691V | Q9UPW6 | protein_coding | deleterious(0.01) | benign(0.039) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SATB2 | SNV | Missense_Mutation | c.1665N>G | p.Ile555Met | p.I555M | Q9UPW6 | protein_coding | deleterious(0.02) | probably_damaging(0.918) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| SATB2 | SNV | Missense_Mutation | c.1504N>G | p.Gln502Glu | p.Q502E | Q9UPW6 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| SATB2 | SNV | Missense_Mutation | c.1882N>T | p.Ile628Phe | p.I628F | Q9UPW6 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-B6-A0IC-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SATB2 | SNV | Missense_Mutation | novel | c.1394N>A | p.Thr465Asn | p.T465N | Q9UPW6 | protein_coding | tolerated(0.33) | possibly_damaging(0.824) | TCGA-B6-A0IN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
| SATB2 | SNV | Missense_Mutation | c.324C>G | p.His108Gln | p.H108Q | Q9UPW6 | protein_coding | deleterious(0.05) | probably_damaging(0.997) | TCGA-BH-A0DG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR | |
| SATB2 | SNV | Missense_Mutation | rs777257792 | c.1699N>T | p.Arg567Cys | p.R567C | Q9UPW6 | protein_coding | deleterious(0) | possibly_damaging(0.848) | TCGA-BH-A1F8-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
| SATB2 | SNV | Missense_Mutation | c.1853G>A | p.Arg618His | p.R618H | Q9UPW6 | protein_coding | deleterious(0) | possibly_damaging(0.703) | TCGA-E2-A155-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
| SATB2 | SNV | Missense_Mutation | novel | c.965N>T | p.Ala322Val | p.A322V | Q9UPW6 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-LL-A7SZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
| SATB2 | insertion | Frame_Shift_Ins | novel | c.1994_1995insT | p.Gln666ProfsTer23 | p.Q666Pfs*23 | Q9UPW6 | protein_coding | TCGA-AN-A03X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |